Fondaparinux in acute coronary syndromes

Expert Opinion on Drug Metabolism & Toxicology
Vivek Chaturvedi, Ganesan Karthikeyan

Abstract

Antithrombotic therapies form the cornerstone of management of acute coronary syndromes (ACS). An ideal antithrombotic agent should reduce ischemic complications while keeping bleeding events to a minimum. Heparins, both unfractionated and low molecular weight, reduce ischemic outcomes but also significantly increase the risk of major and minor bleeding. Moreover, they do not reduce mortality. Therefore, there is a need for newer agents that preserve the benefits of ischemia reduction while decreasing mortality and bleeding risk. Fondaparinux is a synthetic pentasaccharide which specifically targets factor Xa of the coagulation cascade. It has been effectively used in the prevention of and treatment of venous thromboembolic disease. Two large randomized controlled trials of fondaparinux compared to unfractionated and low molecular weight heparins, among patients with ACS have recently been completed. These studies have shown a significantly lower risk of bleeding with fondaparinux compared to heparins, with equivalent or greater reductions in ischemic outcomes. A small but definite increase in the risk of catheter-related thrombosis has been found among patients undergoing coronary interventions, which is ameliorated by the adm...Continue Reading

References

Feb 7, 2002·Lancet·UNKNOWN Direct Thrombin Inhibitor Trialists' Collaborative Group
Oct 18, 2002·Clinical Pharmacokinetics·François DonatRik de Greef
Apr 8, 2003·Thrombosis Research·Meyer-Michel Samama, Grigoris T Gerotziafas
Jun 15, 2004·Journal of the American College of Cardiology·Maarten L SimoonsUNKNOWN PENTUA Investigators
Oct 29, 2005·The American Journal of Cardiology·Sunil V RaoRobert A Harrington
Mar 16, 2006·The New England Journal of Medicine·UNKNOWN Fifth Organization to Assess Strategies in Acute Ischemic Syndromes InvestigatorsKeith A A Fox
Mar 16, 2006·JAMA : the Journal of the American Medical Association·Salim YusufUNKNOWN OASIS-6 Trial Group
Aug 16, 2006·Circulation·John W EikelboomSalim Yusuf
Nov 25, 2006·The New England Journal of Medicine·Gregg W StoneUNKNOWN ACUITY Investigators
Nov 30, 2006·PLoS Medicine·Colin D Mathers, Dejan Loncar
Mar 3, 2007·The New England Journal of Medicine·Theodore E Warkentin
Jun 22, 2007·The New England Journal of Medicine·Theodore E WarkentinRichard H Aster
Aug 1, 2007·Circulation·Jack HirshJohn W Eikelboom
Nov 9, 2007·Circulation·Jeffrey L AndersonUNKNOWN Couma-Gen Investigators
May 24, 2008·The New England Journal of Medicine·Gregg W StoneUNKNOWN HORIZONS-AMI Trial Investigators
Aug 21, 2008·European Heart Journal·Andrzej BudajUNKNOWN OASIS 5 Investigators
Mar 17, 2009·EuroIntervention : Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·Uwe ZeymerJochen Senges

❮ Previous
Next ❯

Citations

Jun 10, 2010·Vascular Health and Risk Management·Lars MaegdefesselPhilip S Tsao

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.